



Espa[®]
Drotaverine
Antispasmodic

COMPOSITION

Espa[®] tablet : Each tablet contains Drotaverine HCl INN 40 mg.

Espa[®] injection : Each 2 ml ampoule contains Drotaverine HCl INN 40 mg.

PHARMACOLOGY

Espa[®] (drotaverine) is a spasmolytic agent which acts directly on smooth muscle cells by adsorption on the cell surface. Espa[®] inhibits the phosphodiesterase enzyme which leads to an increase of the cAMP level producing smooth muscle cell relaxation. It is thought that Espa[®] also inhibits the initial calcium uptake of the cell. Espa[®] is characterized by a rapid onset of action which is very advantageous in cases of acute painful spastic conditions. Because of its direct action on smooth muscle, Espa[®] does not affect the autonomic nervous system. Therefore Espa[®] is free of the side effects associated with anticholinergic antispasmodics and can be used in glaucoma and prostatic hypertrophy. In addition to its spasmolytic and vasodilatory actions, Espa[®] elicits a selective blockade of cardiac beta receptors.

INDICATION

Spastic conditions of the gastrointestinal tract, irritable bowel syndrome.

Biliary colics and spastic conditions of the biliary tract: Cholecystolithiasis, cholecystitis, cholangitis.

Renal colics and spastic conditions of the urogenital tract: Nephrolithiasis, ureterolithiasis, pyelitis, cystitis.

Spastic conditions of the uterus: Dysmenorrhea, imminent abortion, uterine tetanus.

DOSAGE AND ADMINISTRATION

Espa[®] tablet

Adults: 1 to 2 tablets, 3 times daily

Children (over 6 years): 1/2 to 1 tablet, 1-2 times daily.

Children (1-6 years): 1/4 to 1/2 tablet, 1-2 times daily.

Espa[®] Injection

Adults: 1 to 2 ampoules, intramuscularly or subcutaneously, 1-3 times daily.

For the management of acute stone colics: 1 or 2 ampoules by slow intravenous injection.

Espa[®]

CONTRAINDICATION AND PRECAUTION

Caution should be taken for patients suffering from liver and kidney disease.

SIDE EFFECT

In rare cases nausea and vomiting may occur. Arterial blood pressure may drop following too rapid intravenous injection.

DRUG INTERACTION

Levodopa (anti-perkinson effect may be decreased).

USE IN PREGNANCY AND LACTATION

There is no known case of teratogenicity in animal studies. However, the use of drotaverine should be avoided during pregnancy and lactation.

HOW SUPPLIED

Espa[®] tablet : Box containing 10 x 10 tablets, in blister pack.

Espa[®] injection : Box containing 1 x 5 ampoules of 2 ml.

